ST Pharm Co.,Ltd. (KOSDAQ:237690)

Market Cap	2.46T +66.1%
Revenue (ttm)	346.22B +26.2%
Net Income	69.01B +133.8%
EPS	3,312.63 +122.5%
Shares Out	20.86M
PE Ratio	35.65
Forward PE	32.58
Dividend	500.00 (0.46%)
Ex-Dividend Date	Mar 30, 2026

Volume	145,970
Open	109,500
Previous Close	109,500
Day's Range	108,500 - 121,800
52-Week Range	76,100 - 172,100
Beta	0.22
Analysts	Strong Buy
Price Target	189,090.91 (+60.11%)
Earnings Date	Jul 27, 2026

About ST Pharm

ST Pharm Co.,Ltd., provides manufacturing services for active pharmaceutical ingredient and intermediate. The company offers small molecule and generics, an ingredient for treating viral infections; oligonucleotide based products, such as siRNA/microRNA, antisense, aptamer, decoys, and other novel oligos; monomer; and mRNA for vaccines and therapeutics. It also offers pre-clinical and bioanalytical research and development solutions. The company was formerly known as Samchully Pharmaceutical Company., Ltd. ST Pharm Co. Ltd. was founded in 1983 ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1983
• Employees: 655
• Stock Exchange: KOSDAQ
• Ticker Symbol: 237690

Financial Performance

In 2025, ST Pharm's revenue was 331.68 billion, an increase of 21.16% compared to the previous year's 273.75 billion. Earnings were 54.99 billion, an increase of 58.42%.

Analyst Summary

According to 11 analysts, the average rating for 237690 stock is "Strong Buy." The 12-month stock price target is ₩189,091, which is an increase of 60.11% from the latest price.

Price Target

₩189,091

(60.11% upside)

Analyst Consensus: Strong Buy